Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MOK | Q9UQ07 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81686 | 1.00 | MTOR (0.37) | MTORPIK3CAPIK3R1MEN1KMT2A | |
| SCHEMBL86751 | 0.91 | F10 (0.39) | F10RXRA | |
| SCHEMBL86448 | 0.87 | HIF1A (0.42) | MOKF10MAPTSMN1; SMN2 | |
| SCHEMBL86742 | 0.87 | ABL1 (0.36) | MAPTHPGDSMN1; SMN2 | |
| SCHEMBL29475080 | 0.86 | MAPT (0.43) | MTORPIK3CAPIK3R1MEN1KMT2A | |
| SCHEMBL82129 | 0.86 | MAPT (0.43) | MTORPIK3CAPIK3R1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL83164 | 0.85 | MAPT (0.42) | MTORPIK3CAPIK3R1MEN1KMT2A | |
| SCHEMBL87151 | 0.83 | PIK3CB (0.38) | F10RAB9A | |
| SCHEMBL86413 | 0.81 | MET (0.36) | PIK3CAKMT2AF10MAPTATM | |
| SCHEMBL86669 | 0.80 | PLOD2 (0.43) | PIK3CAMEN1KMT2AMAPTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | claimed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | claimed |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | BAYER CONSUMER CARE AG (CH) | 2021-11-30 | — | — | US | disclosed |
| EP-3843743-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | Bayer AS (NO) | 2021-07-07 | — | — | EP | disclosed |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2021-06-24 | — | — | US | disclosed |
| US-10925880-B2 | Combination of PI3K-inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| WO-2020164997-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-20 | — | — | WO | disclosed |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | BAYER CONSUMER CARE AG (CH) | 2020-07-16 | — | — | US | disclosed |
| WO-2020043617-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2020-03-05 | — | — | WO | disclosed |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-22 | — | — | US | disclosed |
| US-10383877-B2 | Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | PIK3CA, PIK3CD, PIK3CB | MTOR 50/4885PIK3CA 1/4885PIK3R1 11/4885 |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | AR, PIK3CA, AKT3 | MTOR 7/4885PIK3CA 2/4885PIK3R1 15/4885 |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | MTOR 37/4885PIK3CA 1/4885PIK3R1 8/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | MTOR 44/4885PIK3CA 1/4885PIK3R1 6/4885 |
| US-10383877-B2 | Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | MCL1, BCL9, BCL3 | MTOR 2079/4885PIK3CA 435/4885PIK3R1 1595/4885 |
| US-10925880-B2 | Combination of PI3K-inhibitors | BCL9L, BCL9, MALT1 | MTOR 24/4885PIK3CA 33/4885PIK3R1 11/4885 |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BCL9L, BCL9, MALT1 | MTOR 24/4885PIK3CA 33/4885PIK3R1 11/4885 |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | AR, GSK3B, PIK3CA | MTOR 13/4885PIK3CA 3/4885PIK3R1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.